Twist Bioscience Shares Surge to 52‑Week High Amid Analyst Upgrades and Q3 2026 Earnings Call

Twist Bioscience Corporation (NASDAQ:TWST) reached a new 52‑week high, trading as high as $106.58 after several analysts raised their price targets. Robert W. Baird lifted its target to $115, Barclays to $95, and other firms issued buy or overweight ratings. Insider transactions were also disclosed, with Dennis Chosold selling 14,205 shares and senior vice‑president Paula Greensold selling 291 shares.

The company later held its fiscal 2026 third‑quarter earnings conference call, featuring CEO and co‑founder Dr. Emily Leproust, President and COO Dr. Patrick Finn, CFO Adam Laponis, and Chief Corporate Responsibility Officer Angela Bitting. Analysts from TD Cowen, Leerink, Piper Sandler, Guggenheim, Canaccord, William Blair, Stephens, Evercore, Barclays, and Robert W. Baird participated, discussing financial results and growth opportunities.